4D Molecular Therapeutics (FDMT) grants director John F. Milligan 75,000 options

Rhea-AI Filing Summary

4D Molecular Therapeutics director John F. Milligan received a grant of stock options covering 75,000 shares of common stock. The options have an exercise price of $9.42 per share and were automatically granted under the non-employee director compensation program. One-third vests on June 17, 2027, with the rest vesting in equal monthly installments until fully vested on June 17, 2029, or sooner upon a Change in Control, and they expire on June 16, 2036.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider MILLIGAN JOHN F

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	75,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 75,000 shares (Direct, null)

Footnotes (1)

1. Automatically granted pursuant to the terms of the Company's non-employee director compensation program. The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).

Key Figures

Option grant size: 75,000 options Exercise price: $9.42 per share Underlying shares: 75,000 shares +4 more

7 metrics

Option grant size 75,000 options Stock Option (Right to Buy) granted to director

Exercise price $9.42 per share Exercise price for 75,000 stock options

Underlying shares 75,000 shares Common Stock underlying the option award

Post-grant derivative holdings 75,000 options Total options held following this transaction

Initial vesting date June 17, 2027 One-third of options vest on this date

Full vesting date June 17, 2029 All options fully vested by this date

Expiration date June 16, 2036 Option term end date

Key Terms

Stock Option (Right to Buy), non-employee director compensation program, Change in Control, 2020 Incentive Award Plan

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

non-employee director compensation program financial

"Automatically granted pursuant to the terms of the Company's non-employee director compensation program."

Change in Control financial

"will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan)."

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

2020 Incentive Award Plan financial

"Change in Control (as defined in the 2020 Incentive Award Plan)."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/18/2026 - 05:33 PM Accepted by SEC EDGAR 06/18/2026 - 05:32 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MILLIGAN JOHN F

(Last) (First) (Middle)

C/O 4D MOLECULAR THERAPEUTICS, INC.

5858 HORTON STREET #455

(Street)

EMERYVILLE CALIFORNIA 94608

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
4D Molecular Therapeutics, Inc. [ FDMT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$9.42	06/17/2026		A(1)		75,000		(2)	06/16/2036	Common Stock	75,000	$0	75,000	D

Explanation of Responses:

1. Automatically granted pursuant to the terms of the Company's non-employee director compensation program.

2. The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).

	/s/ Scott Bizily as Attorney-in-Fact for John F. Milligan	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did 4D Molecular Therapeutics (FDMT) report for John F. Milligan?

4D Molecular Therapeutics reported a grant of stock options to director John F. Milligan for 75,000 shares of common stock at an exercise price of $9.42 per share, issued as part of the company’s non-employee director compensation program.

What are the vesting terms of John F. Milligan’s 75,000 FDMT stock options?

The stock options vest one-third on June 17, 2027, with the remaining two-thirds vesting in equal monthly installments thereafter. Vesting continues until all 75,000 underlying common shares are fully vested on June 17, 2029, assuming Milligan continues serving the company.

When do John F. Milligan’s FDMT stock options expire and what is the exercise price?

The options granted to John F. Milligan carry an exercise price of $9.42 per share and expire on June 16, 2036. They represent rights to buy 75,000 shares of 4D Molecular Therapeutics common stock if exercised before the expiration date.

How were John F. Milligan’s FDMT stock options granted under the company’s compensation program?

The stock options were automatically granted under 4D Molecular Therapeutics’ non-employee director compensation program. This means they were awarded as part of a standard compensation arrangement for directors rather than as a discretionary, one-off award.

What happens to John F. Milligan’s FDMT options upon a Change in Control?

The filing states that Milligan’s stock options will vest in full upon the consummation of a Change in Control, as defined in the 2020 Incentive Award Plan. This accelerates vesting so all 75,000 underlying shares become exercisable at that event.